Prime Medicine
Alexandria Petrusich has a vast work experience spanning over several companies in the pharmaceutical and biotechnology industry. Alexandria has held various roles in clinical research, development, and operations.
Alexandria's most recent position is as the Vice President of Clinical Science at Prime Medicine, Inc., starting in March 2023.
Prior to joining Prime Medicine, Inc., they worked at bluebird bio from 2022, where they held a role in Clinical Research and Development.
From September 2020 to February 2022, Alexandria served as the Head of Translational Medicine at Graphite Bio.
At bluebird bio, they held multiple positions, including Senior Director of Clinical Science, Clinical Research & Development (2018-2020), Senior Director of Clinical Development Operations (2017-2018), Director of Clinical Development Operations (2015-2017), and Associate Director of Clinical Development Operations (2013-2015).
Before bluebird bio, Alexandria worked as the Director of Clinical Research at Bionovo, Inc. (2011-2013), and as an Associate Director of Clinical Operations at BioMarin Pharmaceutical Inc. (2011).
Alexandria also gained experience as an Associate Director at Eli Lilly and Company (2010-2011), Clinical Program Manager at Sirtris Pharmaceuticals (2007-2010), Clinical Project Manager at Infinity Pharmaceuticals (2006-2007), and Manager of Clinical Operations and Regulatory Affairs at Predix Pharmaceuticals (2003-2006).
Alexandria Petrusich has a Bachelor of Science in Biology from SUNY Geneseo. Alexandria also holds a Certificate in Clinical Research from Boston College's Connell School of Nursing.
This person is not in any offices
Prime Medicine
4 followers
Prime Medicine was founded to bring the promise of gene editing to patients. We use Prime Editing, a next-generation technology that can “search and replace” to restore normal genetic function almost anywhere in the genome. Prime Editing searches to find the precise place in the genome to edit and replaces the segment of faulty DNA with a correct copy of DNA. A single Prime Editor can correct the individual mutations found across patients, meaning Prime Editing can potentially address more than 90 percent of known disease-causing genetic mutations. We envision a world where this technology can cure, halt, and ultimately prevent genetic diseases, providing lifelong benefit to patients. Prime Medicine offers the opportunity to shape the future of gene editing and transform how medicines are used to treat disease. Realizing the promise of Prime Editing requires a talented team with diversity of viewpoints and expertise. We’re building a group of dedicated, scientifically curious individuals who are passionate about helping patients live longer, healthier lives.